Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | MAX | P61244 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GYS1 | P13807 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902359 | 0.91 | ABCB1 (0.42) | ABCB1PDCD1CD274MEN1KMT2A | |
| SCHEMBL5242709 | 0.88 | ROCK2 (0.41) | ABCB1CHEK1PDCD1CD274ROCK2 | |
| SCHEMBL4912515 | 0.83 | BRD4 (0.38) | PDCD1CD274ROCK2 | |
| SCHEMBL4910570 | 0.82 | ROCK2 (0.47) | PDCD1CD274ROCK2MAPT | |
| SCHEMBL4911132 | 0.82 | FEN1 (0.41) | PDCD1CD274ROCK2GYS1 | |
| SCHEMBL4904676 | 0.81 | MAPK14 (0.41) | PDCD1CD274ROCK2GYS1 | |
| SCHEMBL4911644 | 0.81 | MAPK14 (0.41) | PDCD1CD274ROCK2GYS1 | |
| SCHEMBL5242475 | 0.81 | AKR1C3 (0.46) | ABCB1PDCD1CD274ROCK2MAPT | |
| SCHEMBL4910534 | 0.80 | EGFR (0.41) | PDCD1CD274ROCK2 | |
| SCHEMBL4910198 | 0.79 | ALDH1A1 (0.44) | PDCD1CD274MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | ABCB1 667/4885CHEK1 4840/4885PDCD1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.